A sensitive immunoradiometric assay for recombinant alpha-2 interferon (IFN-a2; SCH 30500) was developed by using the monoclonal antibody NK2. A polystyrene bead with polyclonal sheep anti-human IFN-a (Hu IFN-a) antibody adsorbed to it formed the solid phase of the assay. The monoclonal antibody, labeled with 125I, reacted with the IFN-a2 which bound to the polyclonal antibody on the bead. The assay was sensitive, capable of measuring less than 5 IU/mi, and it was precise. Coefficients of variation were less than 10%, often less than 5%. Interassay coefficients of variation for the same sample were also less than 10%. Specificity of the monoclonal antibody for IFN-a2 was greater than for Hu IFN-a produced by leukocytes. In specificity studies it was necessary to add at least 200 IU of Hu IFN-a per ml to 25 IU of IFN-ca2 per ml before the Hu IFN-a affected the accuracy of the assay of IFN-Ot2. Accuracy as determined by correlation studies with the antiviral cytopathic effect assay was very high. Results of the two assays usually agreed within 15 %. This correlation was maintained in studies of IFN-a2 after storage under accelerated degradation conditions, when the IFN was cleaved into smaller sequences of amino acids by cyanogen bromide and when the IFN was carboxymethylated.
Recombinant human alpha-2 interferon (Hu IFN-cx2; SCH 30500) (14) is a protein with antiviral and antiproliferative properties. It has the potential of being an important agent for the prevention and treatment of viral infections and of neoplasias (8, 11 ). An accurate, rapid, and precise assay was needed for its development for clinical testing. The most common assays used to detect and quantitate IFNs are antiviral assays. These assays measure IFN-induced inhibition of viral replication in tissue culture cells (2, 3, 5, 10, 15) . Although sensitive, antiviral assays take 1 to 4 days to perform, require highly skilled personnel, and give highly variable results from laboratory to laboratory and even from day to day in the same laboratory (6) . Depending on the cell line and virus used in the assay, the biological assay will detect the presence of beta and gamma IFNs as well as the alpha IFNs being measured (5) . This lack of specificity may significantly affect an assay when an attempt is being made to detect low levels of IFN-(x2 in serum samples. Therefore, it was decided to investigate the possibility of using an immunological assay to measure IFN-o2.
An immunological assay has been developed by Inoue et al. (9) for Hu IFN-P. Secher to 100,000 cpm. After the tubes had incubated at room temperature for 30 min, one 6.4-mm polystyrene bead with sheep anti-Hu IFN-c adsorbed to it was added to each tube.
The tubes were placed on a shaker and rotated at 125 rpm at room temperature for a minimum of 3 h unless otherwise specified. After incubation, the reagents were aspirated from the tubes, and the assay beads were washed two times with approximately 1,000 p.1 of DB buffer with 0.05% Tween 20. The washing buffer was removed by aspiration. Each tube was counted in a gamma counter for 1 min. Data reduction. The data from the gamma counter were processed on a MACC computer and its data reduction software, manufactured by Micromedics Systems, Inc., Horsham, Pa. Reduction was linear-linear from point to point with bound/reference on the y axis and international units of IFN per milliliter on the x axis. Results were printed in international units per milliliter for each sample assayed, and the dilution factor was used to calculate the potency of the IFN-a2 in the sample.
CPE procedure. The second assay was based on protection against viral CPE. Cells were incubated with dilutions of standard and unknown IFN preparations, then infected with encephalomyocarditis virus, and later examined for viral CPE. The reciprocal of the greatest dilution of the unknown IFN preparation that gave approximately 50% protection against virus infection compared with similar results obtained with standard IFN was considered the titer of that unknown preparation. The activity in international units per milliliter was then calculated by using the titer and dilution factor for the IFN.
Neutralization of IFN-a2 by NK2. NK2 monoclonal antibody (1 mg/ml) was diluted 1/100, placed in the first row of wells of a 96-well microtiter plate, and serially diluted by hand in twofold steps across the plate. IFN-at2 (100 U) was added to each well. After incubation for 30 min at 37°C, 4 x 104 FS-71 cells were added to each well. After incubation at 37°C for an additional 4 h, the cells were infected with encephalomyocarditis virus. After 24 h at 37°C, the plates were stained and evaluated for viral CPE, and a 50% protection endpoint was sought. Table 3 ) with the accepted 24-h CPE assay, all further studies were performed with a final incubation time of 3 h.
Assay precision. Inter-and intra-assay precision were evaluated by using various concentrations of IFN-a2. In this study, the constant agitation step was added to the 3-h incubation step to increase chances of contact of reagents with the antibody on the bead. This increased the precision of the assay, lowering the coefficients of variation (CVs) for the counts per minute of duplicates by an average of 3 to 5%.
Results from inter-and intraassay precision studies are shown in Table 2 . Three analysts assayed the same sample 8 to 10 times on each of three different days. Results obtained from a single assay had CVs of c6%. The day-to-day assay results on the same sample had CVs of less than 5% in this study ( Table 2 ). The assay of a sample for three days by three analysts yielded an assay CV of <5% (Table 2) . Table 3 . With a ratio of 1.03 and a CV <12% for a 6-month period, the IRMA and the CPE assay demonstrated a high degree of correlation.
In the accelerated stability studies on IFN-a2 stored at different temperatures, the CPE assay and the IRMA also yielded parallel results (Table 4) .
Further correlation studies were performed with IFN-a2 modified by cyanogen bromide cleavage and by carboxymethylation of reduced IFN-a2. The results of the IRMA and CPE assay of these materials are shown in Table  4 . Both of the chemical modifications caused a greater than 99% loss of activity of the IFN-a2 in both assay systems. Thus, when the IFN molecule was fragmented into small peptides, both assays detected the loss, as they also did when the molecule was reduced and carboxymethylated.
Finally, a CPE antibody neutralization assay was performed to demonstrate the capacity of the NK2 monoclonal antibody to neutralize the antiviral activity of IFN-a2. In the assay, 6.4 x 106 IU of IFN-a2 was neutralized by 1 mg of NK2 antibody.
Sensitivity of the assay. Having established an assay procedure with precision and accuracy, we evaluated the lower limits of assay sensitivity. In these studies, 5 IU/ml easily separated from NSB by more than two SDs. In 11 assays, the mean NSB was 103 cpm. Two SDs added to that value equals 183. The mean cpm for 5 IU/ml was 224. Lower limits were not investigated, because all samples being assayed contained high concentrations of IFN.
Specificity for IFN-0t2. For the evaluation of specificity of the NK2 monoclonal antibody, samples of IFN-acx were spiked with known quantities of leukocyte-derived Hu IFN-a obtained from Celltech Ltd. The spiked samples were assayed, and each type of IFN was measured alone. Before use, the labeled value of the IFN-a was checked by CPE assay. Results of the studies are shown in Table 5 . Approximately 200 IU of leukocyte derived Hu IFN-a per ml was required before the assay values for IFN-a2 were significantly affected (Table 5 ). When IFN-a2 was used for the standard curve, detection of leukocyte-derived Hu IFN-a ranged from 0 to about 10%, depending on the quantity of leukocyte-derived Hu IFN-a in the assay sample. The assay did not detect IFN-, or IFN--y (data not shown).
DISCUSSION
This report presents a precise and accurate method for the rapid quantitation of IFN-a2. The commercially available reagents 125I-NK2 anti-Hu IFN-a monoclonal antibody and polystyrene beads coated with sheep anti-Hu IFN-a antibody were used to develop a procedure with high sensitivity for IFN-a2. In the IRMA procedure recommended by Celltech Ltd., the IFN is adsorbed to the bead first, the bead is washed, and then the monoclonal antibody is added. In the procedure described here, the IFN was allowed to react with the monoclonal antibody first, and then the bead was added, thereby decreasing the number of steps in the assay. With this procedure, the incubation time could be shortened without decreasing precision, so that results could be obtained within hours rather than the next day. In fact, both inter-and intraassay precision were very high with this method, with CVs less than 5%. This was in dramatic contrast to the biological assays wherein interassay CVs are often greater than 50% (6) .
IFNs are defined by their biological activity. Therefore, despite the imprecision of antiviral assays, it is very important that the IRMA correlate well with the CPE assay and that it detect only biologically active IFN. That this is so was shown by the excellent correlation between the results generated by both assays for batches and formulations and in stability studies. It was further demonstrated by the studies The sensitivity of the IRMA was similar to that of the CPE procedure, and in this study we were able to consistently measure as little as 5 IU/ml. Because a sensitivity of less than 50 IU/ml is not required for the assay of production batches and formulations, detection of less than 5 IU/ml was not investigated in this study of IFN-a..
The high specificity of the NK2 monoclonal antibody for IFN-o., was demonstrated by the studies in which IFN-ao was measured in the presence of various amounts of Hu IFN-ox, a mixture of several alpha IFNs. As much as 200 IU of the IFN-a per ml had to be added before there was any interference with the detection of IFN-c,. These results were in agreement with other reports (16) . Although Allen et al. (1) reported that NK2 binds six of the eight IFN-cx molecules found in lymphoblastoid IFN, Whittall et al. (16) presented results with NK2 which showed that NK2 does not have a high affinity for some of the components of a Hu IFN-a mixture. In their study, NK2 titers measured against lymphoblastoid IFN were manyfold lower than when measured against IFN-ax..
In conclusion, the assay described here was reproducible, rapid, and sensitive for use in the quantitative and qualitative evaluation of recombinant Hu IFN-a2. Similar methodology could be developed for the assay of other recombinant or natural human products.
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